Nektar Therapeutics (NKTR) Reports In-Line Q2 EPS
Tweet
Share
E-mailGet Alerts NKTR Hot Sheet
Price: $60.97 -8.78%
Revenue Growth %: -11.4%
Financial Fact:
Research and development: 51.95M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Revenue Growth %: -11.4%
Financial Fact:
Research and development: 51.95M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q2 EPS of ($0.40), in-line with the analyst estimate of ($0.40). Revenue for the quarter came in at $22.7 million versus the consensus estimate of $21.49 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- KB Home (KBH) Tops Q3 EPS by 16c
- Progress Software completes $400M acquisition of Domo's data platform
- Thor Industries (THO) Misses Q4 EPS by 13c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
